Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CelAgace OraRinse for Oral Candidiasis
NCT03250923Phase 2Unknown
- Sponsor
- CelaCare Technologies, Inc.
- Start
- Sep 2024
- Primary completion
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CelAgace OraRinse in oral candidiasis, sponsored by CelaCare Technologies, Inc.. Status: unknown.
02
Drugs
CelAgace OraRinse
03
Conditions
oral candidiasis
Beyond the preview
Go deeper on NCT03250923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03250923.